Search Result

Results for "

IE

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (2) Biochemical Assay Reagents (1) Caspase (1) CD19 (4) CDK (1) CMV (1) Cytochrome P450 (1) Endogenous Metabolite (6) FGFR (1) Fungal (1) Histone Demethylase (2) HSV (2) Isotope-Labeled Compounds (1) Liposome (2) Mitochondrial Metabolism (1) Monoamine Oxidase (1) Parasite (1) Pim (1) PROTAC-Linker Conjugates for PAC (1) α-synuclein (1)
By Research Areas:	Cancer (11) Infection (2) Inflammation/Immunology (6) Metabolic Disease (4) Neurological Disease (3)
Click Chemistry:	TCO (1) Tetrazine (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101297

Z-IETD-FMK Maximum Cited Publications 37 Publications Verification Z-IE(OMe)TD(OMe)-FMK	Caspase	Cancer
Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a selective and cell permeable caspase-8 inhibitor . Z-IETD-FMK is also a granzyme B inhibitor .

HY-19333

OG-L002 1 Publications Verification	Histone Demethylase Monoamine Oxidase HSV	Infection
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC₅₀ of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC₅₀s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes .

HY-108938

SDZ285428	Cytochrome P450 Fungal Parasite	Infection
SDZ285428 is a CYP51 inhibitor. SDZ285428 inhibits Trypanosoma cruzi (TC) CYP51 with I/E2 <1 (5 min) and I/E2=9 (1 h). SDZ285428 inhibits Trypanosoma brucei (TB) CYP51 with I/E2 <1 (5 min) and I/E2=35 (1 h) .

HY-N7705

Isoescin Ie

Others Others

Isoescin Ie is a derivative of Aescine in Aesculi Semen extract .
HY-N7706

Escin Ie

Others Others

Escin Ie is a derivative of Aescine in Aesculi Semen extract .

Isoescin Ie	Others	Others
Isoescin Ie is a derivative of Aescine in Aesculi Semen extract .

Escin Ie	Others	Others
Escin Ie is a derivative of Aescine in Aesculi Semen extract .

HY-130519

Cdc7-IN-7	CDK	Cancer
Cdc7-IN-7 (compound I-E) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .

HY-P2921

Urate oxidase, Microorganism Uox	Endogenous Metabolite	Others
Urate oxidase, Microorganism (Uox), i.e., uricase, is often used in biochemical studies. Urate oxidase is a peroxisomal enzyme that catalyzes the oxidation of uric acid to allantoin in most mammals .

HY-151742

Norbornene-methyl-NHS	ADC Linker	Others
Norbornene-methyl-NHS is a click chemistry reagent containing a TCO group. Dienophile for conjugation via Diels-Alder-reaction, i.e. copper-free click reaction with tetrazines .

HY-D0980

Biotin-DADOO Biotinyl-3,6-dioxaoctanediamine; EZ-Link Amine-PEO2-Biotin	Biochemical Assay Reagents	Metabolic Disease
Biotin-DADOO is a biotinylation reagent, which can be used to synthesize a biotin-estradiol conjugate (i.e., biotin-DADOO-estradiol) to develop a direct, broad range enzyme immunoassay to measure plasma estradiol concentrations.

HY-W020033S

Lanosterol-d6	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
Lanosterol-d₆ is deuterium labeled Lanosterol. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol s

HY-W020033

Lanosterol 2 Publications Verification	Endogenous Metabolite	Neurological Disease
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .

HY-P2952

Adenylate AMPK; Myokinase; Adk	Endogenous Metabolite	Others
Adenylate (Adk), i.e., myokinase, is a phosphotransferase enzyme, is often used in biochemical studies. Adenylate catalyzes the interconversion of adenosine phosphates. Adenylate monitors phosphate nucleotide levels inside the cell, it plays an important role in cellular energy homeostasis .

HY-160497

MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885	PROTAC-Linker Conjugates for PAC	Cancer
MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 (Comp Ie) is a neodegrader conjugate, can be used in the synthesis of antibody neoDegrader conjugate (AnDC) .

HY-116055

(2R)-Glycerol-O-β-D-galactopyranoside 3-O-β-D-Galactopyranosyl-sn-glycerol	Others	Others
(2R)-Glycerol-O-β-D-galactopyranoside (3-O-β-D-Galactopyranosyl-sn-glycerol) is a good substrate for all three components of the lac operon, i.e. β-galactosidase, the lactose transporter and thiogalactoside transacetylase .

HY-126359

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine SLPC; 18:0-18:2 PC	Endogenous Metabolite	Metabolic Disease
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can be chosen as a model used to investigate the volatile compounds from oxidised phosphatidylcholine molecular species. This method is applied to a real food sample, i.e. soy lecithin .

HY-121432

Kitol	Others	Others
Kitol is peptide used for after-sun repair cosmetics. The dominant degradation reaction for vitamin A derivatives is heat-induced formation of kitols, i.e., dimers or higher oligomers. Vitamin A esters are used as a model system to evaluate microcalorimetry as a tool for monitoring the stability of heat-sensitive substances .

HY-146541

FGFR4-IN-10	FGFR	Cancer
FGFR4-IN-10 (compound 5a) is a potent and selective FGFR4 inhibitor with an IC₅₀ value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3 .

HY-122958

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an inhibitor of α-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

HY-N4104

Agaric acid Agaricinic Acid	Mitochondrial Metabolism	Metabolic Disease
Agaric acid (Agaricinic Acid) is obtained from various plants of the fungous tribe, i.e. Polyporus officinalis and Polyporus igniarius. Agaric acid induces mitochondrial permeability transition through its interaction with the adenine nucleotide translocase. Agaric acid promotes efflux of accumulated Ca ²⁺, collapse of transmembrane potential, and mitochondrial swelling. Agaric acid is used to regulate lipid metabolism .

HY-P2918

Phosphoglucose Isomerase, Baker's yeast (S. cerevisiae) GPI; Phosphoglucose Isomerase	Endogenous Metabolite	Others
Phosphoglucose Isomerase, Baker's yeast (S. cerevisiae) (GPI), i.e., phosphoglucose isomerase/phosphoglucoisomerase (PGI) or phosphohexose isomerase (PHI), is often used in biochemical studies. Glucose 6-phosphate isomeras is a highly conserved glycolytic and dimeric enzyme. Glucose 6-phosphate isomeras catalyzes the reversible isomerization of glucose-6-phosphate to fructose-6-phosphate .

HY-143898

PIM1-IN-4	Pim	Cancer
PIM1-IN-4 (Compound 8) is a potent inhibitor of PIM1. PIM1-IN-4 reveals strong inhibition of five other enzymes, i.e., SGK-1, PKA, CaMK-1, GSK3β, and MSK1. PIM1-IN-4 has the potential for the research of cancer diseases .

HY-12725

ML324 5+ Cited Publications	Histone Demethylase HSV CMV	Cancer
ML324 is a potent JMJD2 demethylase inhibitor with antiviral activity. ML324 also exhibits inhibition for the histone demethylase KDM4B, with an IC₅₀ of 4.9 μM. ML324 has potent anti-viral activity against both herpes simplex virus (HSV) and human cytomegalovirus (hCMV) infection via inhibition viral IE gene expression .

HY-151730

(Me)Tz-butanoic acid	ADC Linker	Others
(Me)Tz-butanoic acid is a click chemistry reagent containing an azide. (Me)Tz-butanoic acid is tetrazine linker for conjugation via Diels-Alder-reaction, i.e. copper-free Click reaction with dienophiles . (Me)Tz-butanoic acid is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.

HY-153084

CD19 CAR mRNA	CD19	Inflammation/Immunology Cancer
CD19 CAR mRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-153085

CD19 CAR circRNA	CD19	Inflammation/Immunology Cancer
CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-12892

SKI-178
SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC₅₀ concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines .

HY-153234

CD19 car circRNA-LNP	CD19 Liposome	Inflammation/Immunology Cancer
CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

HY-153233

CD19 car mRNA-LNP	CD19 Liposome	Inflammation/Immunology Cancer
CD19 car mRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

Cat. No.	Product Name

HY-L118

Sodium Channel Blocker Library	128 compounds
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion. MCE offers a unique collection of 128 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Sodium Channel Blocker Library

128 compounds

Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.

MCE offers a unique collection of 128 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

HY-L076

Drug-Induced Liver Injury (DILI) Compound Library	1391 compounds
Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug. DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver. MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 1391 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

Drug-Induced Liver Injury (DILI) Compound Library

1391 compounds

Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.

DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.

MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 1391 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

HY-L073

Anti-Hepatitis C Virus Compound Library	283 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

283 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Type

HY-D0980

Biotin-DADOO Biotinyl-3,6-dioxaoctanediamine; EZ-Link Amine-PEO2-Biotin	Biochemical Assay Reagents
Biotin-DADOO is a biotinylation reagent, which can be used to synthesize a biotin-estradiol conjugate (i.e., biotin-DADOO-estradiol) to develop a direct, broad range enzyme immunoassay to measure plasma estradiol concentrations.

HY-P2952

Adenylate AMPK; Myokinase; Adk	Biochemical Assay Reagents
Adenylate (Adk), i.e., myokinase, is a phosphotransferase enzyme, is often used in biochemical studies. Adenylate catalyzes the interconversion of adenosine phosphates. Adenylate monitors phosphate nucleotide levels inside the cell, it plays an important role in cellular energy homeostasis .

HY-E70059

alpha-1,2-Fucosyltransferase (α1,2FucT)	Biochemical Assay Reagents
alpha-1,2-Fucosyltransferase (α1,2FucT), i.e., alpha 1, 2-fucosyltransferase, is often used in biochemical studies. alpha-1,2-Fucosyltransferase is a rate-limiting enzyme, can catalyze the synthesis of Lewis y (a cell membrane-associated carbohydrate antigen) .

HY-153234

CD19 car circRNA-LNP	Drug Delivery
CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

CD19 car circRNA-LNP

Drug Delivery

CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

HY-153233

CD19 car mRNA-LNP	Drug Delivery
CD19 car mRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

CD19 car mRNA-LNP

Drug Delivery

CD19 car mRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

Z-IETD-FMK 35+ Cited Publications Z-IE(OMe)TD(OMe)-FMK	Caspase	Cancer
Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a selective and cell permeable caspase-8 inhibitor . Z-IETD-FMK is also a granzyme B inhibitor .

Iα52	Peptides	Inflammation/Immunology
Iα52 is a naturally processed peptide encompassed the residues 52-68 of the murine I-Eα chain and may contribute to selection of immature T cells .

Pegylated synthetic human c-peptide	Peptides	Metabolic Disease
Pegylated synthetic human c-peptide retains bioactivity comparable to that of natural (i.e. non-polyethylene glycolated) C-peptides and has a prolonged circulating residence time in plasma for use in diabetic peripheral neuropathy studies .

Cytochrome c-pigeon (88-104) PCC 88-104	Peptides	Inflammation/Immunology
Cytochrome c-pigeon (88-104) (PCC 88-104) has full stimulatory activity for pigeon cytochrome c-primed T cells from B10.A mice. The I-E ^k-restricted T cell response to Cytochrome c pigeon (pcyt c) is specific for the COOH-terminal sequence 88-104 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W020033

Lanosterol 2 Publications Verification	Triterpenes Structural Classification Human Gut Microbiota Metabolites Microorganisms Terpenoids Source classification Endogenous metabolite	Endogenous Metabolite
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .

HY-N7705

Isoescin Ie	Triterpenes Classification of Application Fields Terpenoids Hippocastanaceae Source classification Other Diseases Plants Disease Research Fields Aesculus chinensis var. wilsonii (Rehder) Turland & N. H. Xia	Others
Isoescin Ie is a derivative of Aescine in Aesculi Semen extract .

HY-N7706

Escin Ie	Triterpenes other families Classification of Application Fields Terpenoids Source classification Other Diseases Plants Disease Research Fields	Others
Escin Ie is a derivative of Aescine in Aesculi Semen extract .